ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026
The Landscape of Advanced Therapy Medicinal Products in Slovenian Transfusion Medicine: A Review of Past and Future Outlook.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesenchymal Stromal Cells: From Bench to Bedside and Back.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced therapy medicinal products (ATMPs) represent a transformative class of biological therapies, including gene therapies, somatic cell therapies, and tissue-engineered products, designed to address complex and often treatment-resistant conditions. This review provides a comprehensive overview of the evolving landscape of ATMP development and clinical implementation in Slovenian transfusion medicine. Summary: Historically rooted in blood and cell processing, the Slovenian Institute for Transfusion Medicine (SITM) has leveraged its infrastructure and regulatory frameworks to pioneer early-phase ATMP trials, as well as ATMP use under the hospital exemption scheme. Clinical experiences include CD34 Key Messages: The SITM plays a central national role in GMP-compliant manufacturing, quality control, and clinical support. To fully realize the potential of ATMPs, coordinated national strategies, targeted investment, and integration with European initiatives are essential. This review highlights Slovenia's progress, identifies key bottlenecks, and outlines opportunities for growth, emphasizing the role of transfusion medicine as a national platform for responsible and innovative ATMP development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.